Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) reported Q3 sales of $16.66 billion, beating expectations. Gardasil sales declined by 11% due to lower demand in China, but Keytruda and Winrevair showed strong performance. Analysts remain optimistic about Merck's pipeline, despite challenges with Gardasil. Goldman Sachs and BMO Capital Markets adjusted their price targets for Merck, reflecting Gardasil's challenges.
November 01, 2024 | 6:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck's Q3 sales beat expectations, but Gardasil sales declined due to lower demand in China. Keytruda and Winrevair showed strong performance. Analysts adjusted price targets due to Gardasil challenges.
Merck's overall sales performance was strong, driven by Keytruda and Winrevair, but Gardasil's decline in China poses a challenge. Analysts adjusted price targets, reflecting mixed signals for short-term stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100